- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01225224
Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers
September 11, 2019 updated by: Astellas Pharma Inc
Phase I Study of ASP015K: Single-Dose and Multiple-Dose Oral Administration in Healthy Nonelderly Men
A study to evaluate the safety, tolerability and PK profiles of single and multiple doses of ASP015K in healthy nonelderly men.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study consists of two parts; single and multiple administration parts.
In single administration part, multiple dose levels of ASP015K or placebo are administered to Japanese and Caucasian men to evaluate whether there is ethnic differences in the pharmacokinetics and pharmacodynamics of ASK015K.
In multiple administration part, drugs are administered only to Japanese volunteers.
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kyushu, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 44 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy judged by the investigator or subinvestigator on the basis of physical examination and all test results
Weight
- Japanese: ≥ 50.0 kg to < 80.0 kg
- Caucasians: ≥ 50.0 kg to < 100.0 kg
BMI
- Japanese: ≥ 17.6 kg/m2 to < 26.4 kg/m2
- Caucasians: ≥ 18.0 kg/m2 to < 30.0 kg/m2
- Written informed consent obtained from the subject personally
Exclusion Criteria:
- Administered drug in another clinical study or a post-market clinical study in the 120 days prior to the study
Collection of 400 mL of whole blood within 90 days prior to the study,
200 mL of whole blood within 30 days prior to the study or blood components within 14 days prior to the study
- Received or is scheduled to receive drug treatment within 7 days prior to the drug administration
- A history of drug allergies
- Upper gastrointestinal symptoms, e.g., nausea, vomiting or stomachache, within 7 days prior to the drug admission
- Concurrent or previous liver disease, e.g., viral hepatitis or drug-induced hepatic injury
- Concurrent or previous heart disease, e.g., congestive heart failure, angina pectoris or arrhythmias requiring treatment
- Concurrent or previous kidney disease, e.g., acute renal failure,
glomerulonephritis or interstitial nephritis (except for previous urinary
calculus)
- Concurrent or previous cerebrovascular disease, e.g., cerebral infarction
- Concurrent or previous malignancy
- Concurrent or previous active or recurrent infection, e.g., hepatitis B,
hepatitis C or syphilis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASP015K Single Japanese Group
Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
|
oral
Other Names:
|
Experimental: ASP015K Single Caucasian Group
Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
|
oral
Other Names:
|
Placebo Comparator: Placebo Single Japanese Group
Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
|
oral
|
Placebo Comparator: Placebo Single Caucasian Group
Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
|
oral
|
Experimental: ASP015K Multiple Group
Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level.
ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.
|
oral
Other Names:
|
Placebo Comparator: Placebo Multiple Group
Participants will receive placebo in three stages, each stage corresponding to a different dosage level.
Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.
|
oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety evaluated by the incidence of AE, vital signs , standard 12-lead ECG and Laboratory tests
Time Frame: For 48 hours after administration
|
For 48 hours after administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma unchanged drug concentration
Time Frame: For 48 hours after administration
|
For 48 hours after administration
|
Urinary unchanged drug concentration
Time Frame: For 48 hours after administration
|
For 48 hours after administration
|
Transcription factor phosphorylation level
Time Frame: For 48 hours after administration
|
For 48 hours after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 18, 2009
Primary Completion (Actual)
March 10, 2010
Study Completion (Actual)
March 10, 2010
Study Registration Dates
First Submitted
October 19, 2010
First Submitted That Met QC Criteria
October 19, 2010
First Posted (Estimate)
October 20, 2010
Study Record Updates
Last Update Posted (Actual)
September 13, 2019
Last Update Submitted That Met QC Criteria
September 11, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 015K-CL-HV03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
-
AbbVieCompletedHealthy VolunteerUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States